Angiotensin Receptor Blocker and Dihydropyridine Calcium Channel Blocker Combinations: An Emerging Strategy in Hypertension Therapy

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg

(2009) J. Schrader et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point

(2009) Franz H. Messerli   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis

(2008) Saravanan Balamuthusamy et al.   AMERICAN HEART JOURNAL

Compliance with Antihypertensive Therapy in the Elderly

(2008) Michael Dickson et al.   American Journal of Cardiovascular Drugs

Out-of-pocket and Total Costs of Fixed-dose Combination Antihypertensives and Their Components

(2008) A. Rabbani et al.   AMERICAN JOURNAL OF HYPERTENSION

Altered Blood Pressure Progression in the Community and Its Relation to Clinical Events

(2008) Erik Ingelsson   ARCHIVES OF INTERNAL MEDICINE

The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study

(2008) Steven G. Chrysant et al.   CLINICAL THERAPEUTICS

Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension

(2008) David H G Smith   DRUGS

Patterns and Associated Health Services Costs of Antihypertensive Drug Modifications

(2008) Shadi S. Saleh et al.   Journal of Clinical Hypertension

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors

(2008) Ronald D. Smith et al.   Journal of the American Society of Hypertension

Systolic pressure is all that matters

(2008) Bryan Williams et al.   LANCET

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

(2008)   LANCET

Global burden of blood-pressure-related disease, 2001

(2008) Carlene MM Lawes et al.   LANCET

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

(2008) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

(2008) Kenneth Jamerson et al.   NEW ENGLAND JOURNAL OF MEDICINE